OSPred Tool: A Digital Health Aid for Rapid Predictive Analysis of Correlations Between Early End Points and Overall Survival in Non–Small-Cell Lung Cancer Clinical Trials.

Autor: Shameer, Khader, Zhang, Youyi, Prokop, Andrzej, Nampally, Sreenath, N, Imran Khan A., Weatherall, Jim, Iacona, Renee Bailey, Khan, Faisal M.

Publikováno v: JCO Clinical Cancer Informatics; 4/25/2022, Vol. 6, p1-8, 8p

Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials.

Autor: Bell DW; Massachusetts General Hospital Cancer Center and Department of Pathology, Harvard Medical School, Charlestown, MA 02129, USA., Lynch TJ, Haserlat SM, Harris PL, Okimoto RA, Brannigan BW, Sgroi DC, Muir B, Riemenschneider MJ, Iacona RB, Krebs AD, Johnson DH, Giaccone G, Herbst RS, Manegold C, Fukuoka M, Kris MG, Baselga J, Ochs JS, Haber DA

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2005 Nov 01; Vol. 23 (31), pp. 8081-92. Date of Electronic Publication: 2005 Oct 03.